0001399529-21-000116.txt : 20210615 0001399529-21-000116.hdr.sgml : 20210615 20210615191911 ACCESSION NUMBER: 0001399529-21-000116 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210611 FILED AS OF DATE: 20210615 DATE AS OF CHANGE: 20210615 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ciappenelli Robert D. CENTRAL INDEX KEY: 0001778786 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36281 FILM NUMBER: 211020110 MAIL ADDRESS: STREET 1: DICERNA PHARMACEUTICALS, INC. STREET 2: 87 CAMBRIDGEPARK DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02140 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Dicerna Pharmaceuticals Inc CENTRAL INDEX KEY: 0001399529 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 205993609 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 75 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 617 621 8097 MAIL ADDRESS: STREET 1: 75 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 wf-form4_162379913307013.xml FORM 4 X0306 4 2021-06-11 0 0001399529 Dicerna Pharmaceuticals Inc DRNA 0001778786 Ciappenelli Robert D. C/O DICERNA PHARMACEUTICALS, INC. 75 HAYDEN AVENUE LEXINGTON MA 02421 0 1 0 0 Chief Commercial Officer Common Stock 2021-06-11 4 M 0 10000 15.61 A 13773 D Common Stock 2021-06-11 4 S 0 10000 35 D 3773 D Common Stock 2021-06-14 4 M 0 20000 15.61 A 23773 D Common Stock 2021-06-14 4 S 0 20000 38 D 3773 D Employee Stock Option (Right to Buy) 15.61 2021-06-11 4 M 0 10000 0 D 2029-06-30 Common Stock 10000.0 290000 D Employee Stock Option (Right to Buy) 15.61 2021-06-14 4 M 0 20000 0 D 2029-06-30 Common Stock 20000.0 270000 D The Reporting Person sold an aggregate of 10,000 shares of Common Stock on June 11, 2021 (the "Shares Sold No. 1") as reported in this Form 4. The Shares Sold No. 1 represent 2.08% of 481,298 shares of Common Stock, which is the number of shares of Common Stock owned by the Reporting Person prior to the Shares Sold No. 1 transaction reported in this Form 4, as well as shares issuable upon exercise or settlement of vested and unvested options and restricted stock units held by the Reporting Person as of the date of this report. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 10, 2020. The Reporting Person sold an aggregate of 20,000 shares of Common Stock on June 14, 2021 (the "Shares Sold No. 2") as reported in this Form 4. The Shares Sold No. 2 represent 4.24% of 471,298 shares of Common Stock, which is the number of shares of Common Stock owned by the Reporting Person prior to the Shares Sold No. 2 transaction reported in this Form 4, as well as shares issuable upon exercise or settlement of vested and unvested options and restricted stock units held by the Reporting Person as of the date of this report. The option vests 25% on the first year anniversary of the vesting start date of June 3, 2019 and the remaining 75% vests in 36 substantially equal monthly installments thereafter, subject in each case to the Reporting Person's continued employment or service with the Issuer through the applicable vesting date. /s/ Douglas W. Pagan, attorney-in-fact 2021-06-15